MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
An Interview With Binita Shah, MD, MS, FACC, FSCAI
Dr. Shah discusses the benefit of colchicine in cardiovascular disease, the role of diet after coronary intervention, DEI efforts in interventional cardiology, and more.
Radial Access for the Evaluation of Bypass Grafts
Moderator: Mirvat Alasnag, MD, FACP, FSCAI, FRCPPanelists: James Nolan, MBChB, FRCP, MD; Sunil Rao, MD; and Binita Shah, MD, MS, FACC, FSCAI
Radial Access Best Practices in 2019
An update on procedural considerations for transradial artery access based on the most recent data.
By Linda M. Koshy, MD; Matthew Schoenfeld, MD; and Binita Shah, MD, MS
SCAI Expert Consensus Statement Addresses Management of Calcified Coronary Lesions Requiring Intervention
February 5, 2024—The Society for Cardiovascular Angiography & Interventions (SCAI) recently announced the publication of the “SCAI Expert Consensus Statement on the Management of Calcified Coronary Lesions.” According to the society, the statement outlines methods for interventional cardiologists to identify various types of calcified coronary lesions and presents an algorithm to help them guide the use of these various calcium modification strategies.
Radial Artery Access
By Ted E. Feldman, MD, MSCAI, FACC, FESC
Meeting the Challenge…
By Azeem Latib, MD
Women’s Heart Health
By Mirvat Alasnag, MD, FACP, FACC, FSCAI, FSCCT
SCAI Announces Selections for Emerging Leader Mentorship Program
February 23, 2015—The Society for Cardiovascular Angiography and Interventions (SCAI) announced the selection of 12 early-career interventional cardiologists to participate in the 2015–2017 Emerging Leader Mentorship (ELM) Program.
SCAI Leadership Remarks on FDA Panel Meeting on RDN
August 24, 2023—The leadership of the Society for Cardiovascular Angiography & Interventions (SCAI) issued a statement regarding the FDA Circulatory System Devices Panel that convened on August 22 to 23 to review scientific evidence on two interventional renal denervation (RDN) devices aimed at reducing blood pressure in adult patients with uncontrolled hypertension (HTN) who may be inadequately responsive to, or intolerant to, antihypertensive medications.
